Antonino M. Belfiore

Via G. Venezian 1
Milan, 20133, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 173 publications

Correction: MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.

Correction: MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.

Journal: Journal of experimental & clinical cancer research : CR
Published: August 20, 2026

Toremifene in desmoid fibromatosis: Prospective phase 2 study of two dose levels.

Toremifene in desmoid fibromatosis: Prospective phase 2 study of two dose levels.

Journal: European journal of cancer (Oxford, England : 1990)
Published: December 20, 2025

RETRACTED: Sarfstein et al. Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells. Cancers 2010, 2, 233-261.

RETRACTED: Sarfstein et al. Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells. Cancers 2010, 2, 233-261.

Journal: Cancers
Published: October 08, 2025

Metabolic profiling of therapy-induced senescent cancer cells via TPEF, MALDI-MS, and RNA-sequencing.

Metabolic profiling of therapy-induced senescent cancer cells via TPEF, MALDI-MS, and RNA-sequencing.

Journal: Scientific reports
Published: September 10, 2025

Correction: Mediterranean diet, selenium and Graves' ophthalmopathy: a prospective, randomized, single-center study.

Correction: Mediterranean diet, selenium and Graves' ophthalmopathy: a prospective, randomized, single-center study.

Journal: Endocrine
Published: August 10, 2025

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.

Journal: Journal of experimental & clinical cancer research : CR
Published: May 29, 2025

Interleukin-1β mediates a tumor-supporting environment prompted by IGF1 in triple-negative breast cancer (TNBC).

Interleukin-1β mediates a tumor-supporting environment prompted by IGF1 in triple-negative breast cancer (TNBC).

Journal: Journal of translational medicine
Published: May 22, 2025

Mediterranean diet, selenium and Graves' ophthalmopathy: a prospective, randomized, single-center study.

Mediterranean diet, selenium and Graves' ophthalmopathy: a prospective, randomized, single-center study.

Journal: Endocrine
Published: April 18, 2025

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

Journal: NPJ precision oncology
Published: April 03, 2025

The monocyte/HDLc ratio and LDLc are two independent predictors of the response of Graves' ophthalmopathy patients to parenteral glucocorticoids.

The monocyte/HDLc ratio and LDLc are two independent predictors of the response of Graves' ophthalmopathy patients to parenteral glucocorticoids.

Journal: Endocrine
Published: November 22, 2024

Effect of anti-inflammatory molecules from food on organoids derived from adenomatous polyps of FAP subjects.

Effect of anti-inflammatory molecules from food on organoids derived from adenomatous polyps of FAP subjects.

Journal: Tumori
Published: October 28, 2024

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 15, 2024
Showing 1-12 of 173

Last Updated: 09/26/2026